Loxo Oncology, Inc.
Clinical trials sponsored by Loxo Oncology, Inc., explained in plain language.
Cancer-focused biotech acquired by Eli Lilly.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for blood cancer patients: triple therapy aims to keep disease in check longer Results expected Oct 2026 (estimated)
- New hope for blood cancer patients: experimental drug takes on standard therapy Results expected Jan 2027 (estimated)
-
New hope in blood cancer battle: Next-Gen drug tested against standard therapy
Disease control Recruiting nowThis study tests whether a newer drug called pirtobrutinib works better than the current standard drug ibrutinib for people with chronic lymphocytic leukemia or small lymphocytic lymphoma. About 737 adults who need treatment for their cancer will be randomly assigned to receive o…
Phase 3 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New hope for Tough-to-Treat blood cancers: pirtobrutinib trial launches
Disease control Recruiting nowThis study tests three different doses of a drug called pirtobrutinib in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) whose cancer came back or didn't respond after treatment with a BTK inhibitor. About 249 participants will take part. The go…
Phase 2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC